• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Andexanet alfa for oral fxa inhibitor-associated major acute intracerebral hemorrhage: insights into clinically relevant thromboembolic events from the ANNEXA-I study.口服FXA抑制剂相关的严重急性脑出血用andexanet alfa：来自ANNEXA-I研究对临床相关血栓栓塞事件的见解。
J Vasc Bras. 2025 Jan 20;23:e20240133. doi: 10.1590/1677-5449.202401332. eCollection 2024.
2
Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy.急性颅内出血患者生物标志物与脑内血肿扩大及动脉血栓栓塞事件的关联：ANNEXA-I生物标志物子研究
Stroke. 2025 Jul;56(7):1807-1815. doi: 10.1161/STROKEAHA.124.049966. Epub 2025 Apr 28.
3
Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.依达赛珠单抗对比非特异性治疗用于服用因子 Xa 抑制剂的颅内出血患者：ANNEXA-4 和 TICH-NOAC 的个体患者数据分析。
Int J Stroke. 2024 Jun;19(5):506-514. doi: 10.1177/17474930241230209. Epub 2024 Mar 8.
4
Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.依达赛珠单抗在颅内出血中的止血效果和抗 FXa（因子 Xa）作用逆转：ANNEXA-4 子研究。
Stroke. 2021 Jun;52(6):2096-2105. doi: 10.1161/STROKEAHA.120.030565. Epub 2021 May 10.
5
Andexanet Alfa (Andexxa) Formulary Review.安多昔单抗（Andexxa）处方集审查。
Crit Pathw Cardiol. 2019 Jun;18(2):66-71. doi: 10.1097/HPC.0000000000000177.
6
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.安达赛珠单抗用于治疗Xa因子抑制剂引起的严重出血的最终研究报告。
Circulation. 2023 Mar 28;147(13):1026-1038. doi: 10.1161/CIRCULATIONAHA.121.057844. Epub 2023 Feb 20.
7
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.安达赛珠单抗用于逆转Xa因子抑制剂活性：日本ANNEXA-4研究的预设亚组分析
J Atheroscler Thromb. 2024 Mar 1;31(3):201-213. doi: 10.5551/jat.64223. Epub 2023 Aug 26.
8
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.依诺肝素相关非外伤性颅内出血患者在 ANNEXA-4 试验内接受治疗与真实世界常规治疗的血肿扩大和临床结局。
Stroke. 2022 Feb;53(2):532-543. doi: 10.1161/STROKEAHA.121.034572. Epub 2021 Oct 14.
9
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.Andexanet alfa 与四种因子凝血酶原复合物浓缩物在逆转阿哌沙班或利伐沙班相关颅内出血中的比较：倾向评分重叠加权分析。
Crit Care. 2022 Jun 16;26(1):180. doi: 10.1186/s13054-022-04043-8.
10
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.一项 18 个月的单中心观察性研究，评估抗因子 Xa 抑制剂相关颅内出血患者真实世界中使用andexanet alfa 的情况。
Clin Neurol Neurosurg. 2020 Aug;195:106070. doi: 10.1016/j.clineuro.2020.106070. Epub 2020 Jul 4.

本文引用的文献

1
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.直接口服抗凝剂的逆转：ISTH SSC 的指南。
J Thromb Haemost. 2024 Oct;22(10):2889-2899. doi: 10.1016/j.jtha.2024.07.009. Epub 2024 Jul 17.
2
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.依达赛珠单抗治疗因子 Xa 抑制剂相关急性脑出血。
N Engl J Med. 2024 May 16;390(19):1745-1755. doi: 10.1056/NEJMoa2313040.
3
Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.用于预防和治疗静脉及动脉血栓栓塞的因子XI/XIa抑制剂：一项叙述性综述。
Vasc Med. 2024 Feb;29(1):85-92. doi: 10.1177/1358863X231206778. Epub 2023 Nov 10.
4
ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism.使用XI因子/XIa因子抑制剂进行静脉血栓栓塞的血栓预防
J Vasc Bras. 2023 Jun 19;22:e20230051. doi: 10.1590/1677-5449.202300512. eCollection 2023.
5
Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants.四项凝血因子促凝血酶原复合物浓缩物治疗直接口服抗凝剂相关出血的临床前和临床研究的临床相关性。
Ann Emerg Med. 2023 Sep;82(3):341-361. doi: 10.1016/j.annemergmed.2023.04.015. Epub 2023 May 18.
6
Reversal agents for current and forthcoming direct oral anticoagulants.目前和即将推出的直接口服抗凝剂的逆转剂。
Eur Heart J. 2023 May 21;44(20):1795-1806. doi: 10.1093/eurheartj/ehad123.
7
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.安达赛珠单抗用于治疗Xa因子抑制剂引起的严重出血的最终研究报告。
Circulation. 2023 Mar 28;147(13):1026-1038. doi: 10.1161/CIRCULATIONAHA.121.057844. Epub 2023 Feb 20.
8
A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.治疗性因子 XI(a)抑制剂患者出血管理的建议。
J Thromb Haemost. 2022 Jan;20(1):32-38. doi: 10.1111/jth.15579. Epub 2021 Nov 21.
9
Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.八旬老年房颤患者中直接口服抗凝剂与维生素 K 拮抗剂的临床特征：一项多中心倾向评分匹配真实世界队列研究。
J Thromb Thrombolysis. 2020 Jan;49(1):42-53. doi: 10.1007/s11239-019-01923-9.
10
Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.Andexanet Alfa 逆转因子 Xa 抑制剂可能会增加血栓形成的风险，与治疗前相比。
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619863493. doi: 10.1177/1076029619863493.

Andexanet alfa for oral fxa inhibitor-associated major acute intracerebral hemorrhage: insights into clinically relevant thromboembolic events from the ANNEXA-I study.

作者信息

Porres-Aguilar Mateo, Meillon-Garcia Luis Antonio, Guerra João Carlos de Campos

机构信息

Texas Tech University Health Sciences Center, Department of Internal Medicine, Divisions of Hospital and Adult Thrombosis Medicine, El Paso, Texas, USA.

Centro Médico ABC, México City, México.

出版信息

J Vasc Bras. 2025 Jan 20;23:e20240133. doi: 10.1590/1677-5449.202401332. eCollection 2024.

DOI:10.1590/1677-5449.202401332
PMID:39866166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11758565/
Abstract
摘要